ELTP News 0.3810 06/18/2014 04:48:42 Elite Pharma Inc (ELTP)

New Post Public Reply Private Reply Replies (0) Message Board
Stock_Tracker
Elite Pharma Inc (ELTP) 0.3810 $ELTP

Elite Pharmaceuticals signs USD5m settlement agreement with Novel Laboratories and other related parties
M2 - Wed Jun 11, 7:22AM CDT
Controlled release products company Elite Pharmaceuticals (OTC BB:ELTP) announced on Tuesday a USD5m settlement agreement with Novel Laboratories, Veerappan S. Subramanian, VGS Pharma and other related parties (the VGS parties).

Elite Pharmaceuticals Enters Into $5 Million Settlement Agreement With Novel Laboratories
GlobeNewswire - Tue Jun 10, 10:11AM CDT
Elite Pharmaceuticals, Inc. ("Elite" or the "Company" (OTCBB:ELTP) entered into a settlement agreement with Novel Laboratories, Inc. ("Novel" , Veerappan S. Subramanian ("Subramanian" , VGS Pharma, LLC ("VGS" and other related parties (all of the foregoing collectively, the "VGS Parties" pursuant to which the 2006 Strategic Alliance Agreement and Stockholders Agreement with Subramanian and VGS (collectively, the "Agreement" were terminated and all parties executed mutual releases. In addition, the VGS Parties paid Elite $5,000,000 in exchange for 9,800 shares of Novel Class A common stock owned by Elite. This resolves all disputes and claims between Elite and the VGS Parties, including those alleged in the action commenced by Elite against the VGS Parties on April 28, 2014, and ends Elite's ownership in Novel.

Elite Pharmaceuticals Begins Human Abuse Liability Studies for ELI-200
GlobeNewswire - Mon Jun 09, 7:01AM CDT
Elite Pharmaceuticals, Inc. ("Elite" or the "Company" (OTCBB:ELTP) today announced dosing of the first subject in the treatment phase for a human abuse liability clinical study for ELI-200. ELI-200 is an abuse deterrent product for an undisclosed opioid. The study is a randomized, double-blind, double-dummy, active and placebo-controlled five-way crossover study comparing crushed ELI-200 capsules to a comparator product. The primary objective of the study is to assess the abuse potential when administered intranasally of ground ELI-200 relative to a crushed comparator product and the secondary objectives include determining relative bioavailability and safety of the product. Completion of the dosing is expected in approximately 2 months. Final study results are expected later this year.

Adherex Technologies Sees Share Volume Shoot Through The Roof
ACCESSWIRE - Tue May 27, 3:18PM CDT
Adherex Technologies Inc. (OTCQB: ADHXF) saw its share volume skyrocket on May 27th with 627,393 shares exchanging hands, twelve times higher than its three month daily average volume of 50,914 shares.

Elite Pharmaceuticals Announces Results of 2014 Annual Meeting of Shareholders
GlobeNewswire - Fri May 23, 10:08AM CDT
Elite Pharmaceuticals, Inc. ("Elite" or the "Company" ("Elite" (OTCBB:ELTP) today announced the voting results of matters considered during the Company's annual meeting of shareholders held on May 21, 2014. Of the shares entitled to vote at this meeting, 89.18% shares were voted for this meeting.

ChromaDex Announces Second Human Clinical Trial
ACCESSWIRE - Wed May 21, 8:28AM CDT
ChromaDex Inc. (OTCQB: CDXC) saw its share volume soar on May 20th with 224,975 shares exchanging hands, significantly higher than its three month daily average volume of 143,835 shares.

Elite Pharmaceuticals Initiates Pivotal Bioequivalence Study for Third Opioid Abuse Deterrent Product
GlobeNewswire - Mon May 19, 7:15AM CDT
Elite Pharmaceuticals, Inc. ("Elite" or the "Company" ("Elite" (OTCBB:ELTP) announced today the first dosing of a pivotal bioequivalence study in healthy volunteers for ELI-202, an undisclosed opioid abuse deterrent product, utilizing Elite's proprietary pharmacological abuse deterrent technology.

Provectus Biopharmaceutical's Share Volume Skids
ACCESSWIRE - Mon May 12, 10:13AM CDT
Provectus Biopharmaceuticals, Inc. (OTCQB: PVCT) saw its share volume slide on May 9th with 283,582 shares exchanging hands, significantly lower than its three month daily average of 696,514 shares.

Elite Pharmaceuticals Showing Long Term Promise, Analyst Report by BrokerBank Securities, Inc.
PR Newswire - Mon May 05, 6:30AM CDT
Elite Pharmaceuticals, Inc. (OTCQB: ELTP) develops oral sustained and controlled release products. Elite has eight commercial products currently being sold, twelve additional approved products pending manufacturing site transfer and two additional products under review pending approval by the FDA. Elite's lead pipeline products include abuse resistant opioids utilizing the Company's patented proprietary technology.

Fed Shows Confidence in Market with Cut in Bond Buying Stimulus
PR Newswire Europe - Thu May 01, 6:33AM CDT
LONDON, May 1, 2014 /PRNewswire/ --

FDA Approves Clinical Trial of BrainStorm Cell Therapeutics' ALS Treatment
ACCESSWIRE - Tue Apr 29, 9:05AM CDT
BrainStorm Cell Therapeutics' (OTCQB: BCLI) stock volume skyrocketed Apr. 28, with 3,714,379 shares changing hands, more than 5 times its three-month average volume of 718,105 shares.

Elite Pharmaceuticals Granted New Patent for Abuse Deterrent Technology
GlobeNewswire - Tue Apr 22, 6:41AM CDT
Elite Pharmaceuticals, Inc. ("Elite" or the "Company" (OTCBB:ELTP) announced today the issuance of U.S. Patent No. 8,703,186 titled "Abuse-Resistant Oral Dosage Forms and Method of Use Thereof". This patent expands the intellectual property for the Company's opioid abuse deterrent technology. Elite now has three US patents and one Canadian patent issued in this area with additional patents pending in the U.S., Canada and Europe.

Limitless Venture Group Settles $163,391 Note with Beaufort Capital Partners
ACCESSWIRE - Wed Apr 16, 9:07AM CDT
Limitless Venture Group Inc.'s (OTCPINK: LVGI) announced that the company and a third- party debt holder Beaufort Capital Partners reached an amicable settlement regarding an outstanding note which had essentially floorless convertible terms attached.

Elite Pharmaceuticals to Receive up to 40 Million from Lincoln Park Capital Fund
ACCESSWIRE - Tue Apr 15, 9:01AM CDT
Elite Pharmaceuticals Inc. (OTCBB: ELTP) announced Apr. 14 that it has entered into a common stock purchase agreement with Lincoln Park Capital Fund LLC ("LPC" , a Chicago-based institutional investor for up to $40 million.

Elite Pharmaceuticals, Inc. Secures Funding Commitment of Up to $40 Million From Lincoln Park Capital Fund, LLC
GlobeNewswire - Mon Apr 14, 6:30AM CDT
Elite Pharmaceuticals, Inc. ("Elite" or the "Company" (OTCBB:ELTP) announced today that it has entered into a common stock purchase agreement with Lincoln Park Capital Fund, LLC ("LPC" , a Chicago-based institutional investor for up to $40 Million. Proceeds from the transaction will be used to develop the Company's pipeline of products, including the abuse resistant opioids, and for general corporate purposes.

Elite Pharmaceuticals Appoints Barbara Ellison as Vice President of Quality Operations and Regulatory Affairs
GlobeNewswire - Thu Mar 27, 11:15AM CDT
Elite Pharmaceuticals, Inc. ("Elite" or the "Company" (OTCBB:ELTP) today announced that it has created the position of Vice President, Quality Operations & Regulatory Affairs and has hired industry veteran, Barbara Ellison, to fill that role. Ms. Ellison has extensive experience in quality assurance, regulatory compliance, validation, performance optimization and quality control. Ms. Ellison will have overall responsibility for Elite's quality and regulatory functions including the Company's Quality Assurance and Compliance group and the Analytics and Quality Control group. Ms. Ellison will serve as a member of Elite's senior leadership team, reporting directly to Nasrat Hakim, Elite's President and Chief Executive Officer.

OTC Daily Alert Stock Watch - Elite Pharmaceuticals, Inc. (OTCQB: ELTP)
WorldStockWire - Tue Mar 25, 7:00AM CDT
OTC Daily Alert tracks stocks daily and is pleased to offer features on public companies. Investors can receive FREE Stock Alerts and company news and profiles by visiting OTC Daily Alert at the following: http://www.otcdailyalert.com

Elite Pharmaceuticals submits site transfer application of Isradipine under FDA's CBE-30
M2 - Tue Mar 25, 5:55AM CDT
Controlled release products company Elite Pharmaceuticals (OTC BB:ELTP) reported on Monday the submission of a supplemental application with the US Food and Drug Administration (FDA) for the site transfer of manufacturing for Isradipine 2.5 mg and 5 mg tablets to its Northvale facility.
Scroll down for more posts ▼

Top 10 Most Recent News Articles

SKINformed Bets on Skin Longevity Over Quick Fixes

Updated Category News Views 75

Wrinkle panic has been a very profitable racket for a long time, and SKINformed is trying to sidestep it. The physician-founded skincare brand is planting its flag on “SKINgevity,” a term it uses to describe long-term skin health rather than a frantic hunt for an overnight rewind. That is a sensible read on where beauty consumers appear to be headed: less appetite for...

Continue Reading
Minno Bets on Listener Kids to Build Premium Growth

Updated Category News Views 131

Children’s media rarely gets a clean strategic move, but this one comes pretty close. Minno has signed a worldwide, multi-year agreement making it the exclusive faith-based streaming home for Listener Kids’ video library, while commissioning 66 new episodes for its own service. For a company trying to build a serious Christian family-media business, that is more than...

Continue Reading
Colossal's Halloween Campaign Wins Top Communicator Honor

Updated Category News Views 76

A horror-themed fan competition putting money toward hospitalized children is not the usual awards-season material, which is precisely why Colossal's latest recognition lands with some weight. The Phoenix-based professional fundraiser received an Award of Excellence, the top honor at the 32nd annual Communicator Awards, for its Face of Halloween campaign in the Innovation...

Continue Reading
Specialized Metal Makers Become the New M&A Prize Again

Updated Category News Views 30

A forgotten heat-treatment line can suddenly be worth more than a shiny new mill when buyers realize nobody can duplicate its certifications, workforce, and customer approvals overnight. That is the basic truth sitting underneath BGL's Nov. 19, 2026 assessment of the U.S. metals market. The easy headline is consolidation. The useful takeaway is much narrower: specialized...

Continue Reading
HLRBO's Data-Heavy Rebuild Changes Hunting Lease Market

Updated Category News Views 137

A hunting lease used to begin with hearsay, blurry photos, and a whole lot of hoping. HLRBO is trying to drag that stubbornly analog process into a data-rich, phone-first marketplace, and frankly, it is about time. The company rebuilt its web and mobile platforms around parcel information, plain-language AI search, mobile lease completion, and its Land IQ™ scoring...

Continue Reading
Mindstream’s Jordan AI Campus Faces Its First Real Test

Updated Category News Views 39

Jordan’s AI ambitions just got attached to a very large gas meter. Mindstream Energy has unveiled a plan for an AI-ready data-center campus at Al-Risha in Mafraq Governorate, built around dedicated natural-gas generation rather than a conventional dependence on the utility grid. The headline number is 400 megawatts of eventual capacity. The number that matters first is...

Continue Reading
Jeff Stern Turns Travel Photography Into Full Attention

Updated Category News Views 57

A cancelled photography conference in March 2020 sent Jeff Stern toward the American Southwest, and that detour eventually became A Change of Scenery. Frankly, that origin has more grit than the usual polished creative-origin tale. While much of the world had stopped moving, Stern went alone, stood at White Pocket beneath a cobalt sky, and began reconsidering what he...

Continue Reading
Yangtze Documentary Frames a Decade of Economic Change

Updated Category News Views 13

A fish, a kilowatt-hour, a microchip, and a shipping container walk into the same economic story—well, not literally, thank goodness—and that is the unusual wager behind CCTV4’s upcoming Our Home, Our Yangtze. Announced in Beijing on November 19, 2026, the four-part documentary aims to recount a decade of change across the Yangtze River Economic Belt without leaning...

Continue Reading
DHC’s Ulta Rollout Gets a Useful Pricing Correction

Updated Category News Views 32

A face-wash price tag just became the most revealing part of DHC’s Ulta expansion. The company corrected an earlier announcement that had listed its new Deep Cleansing Face Wash at $31.50; the actual price is $19.00. That may sound like tiny housekeeping, and in the grand scheme it is, but consumer brands live or die on this kind of detail. A cleanser priced near $20...

Continue Reading
Full Truck Alliance Profits Surge as Revenue Slows

Updated Category News Views 122

A freight platform just delivered the kind of earnings math that makes investors sit up: sales barely jogged, while profit took off running. Full Truck Alliance’s third-quarter report is plainly strong on the surface, with net income up 49.0% year over year to RMB1.37 billion. Still, this is not a clean, uncomplicated growth story. The quality of the margin jump...

Continue Reading

Top 5 Most Recently Viewed Articles

OpenBench and ORIC Pharmaceuticals Forge a ground-breaking alliance

Updated Category News Views 102

OpenBench and ORIC Pharmaceuticals Team Up OpenBench, Inc., known for its innovative AI-driven discovery partnerships in the realm of small molecules, has announced a promising new collaboration with ORIC Pharmaceuticals, Inc. (NASDAQ: ORIC). This partnership aims to utilize OpenBench's advanced success-driven discovery methods alongside its cutting-edge structure-based...

Continue Reading
IMUNON's Q3 2025 Update: Progress and Future Endeavors

Updated Category News Views 135

IMUNON Conference Call Announcement LAWRENCEVILLE, N.J. — IMUNON, Inc. (Nasdaq: IMNN), a pioneering clinical-stage biotechnology firm focusing on breakthrough DNA-mediated immunotherapy, is set to host a conference call at 11:00 a.m. ET on Thursday, November 13, 2025. This call will delve into the company’s financial results for the third quarter ending September 30,...

Continue Reading
Enhancements in Compliance Solutions Transforming MSP Landscape

Updated Category News Views 730

Exciting Upgrades to the Cyber Verify Compliance Platform Cyber Verify, a platform operated by MSPAlliance, has recently undergone significant enhancements aimed at revolutionizing the way Managed Service Providers (MSPs) approach compliance. With these new features, Cyber Verify is not just a tool, but a key partner for MSPs striving to achieve excellence in operational...

Continue Reading
Celebrating Latino Heritage: James Scott Farrin's Impact in 2024

Updated Category News Views 173

Supporting Latino and Hispanic Communities The Law Offices of James Scott Farrin has made remarkable strides in their commitment to supporting Latino and Hispanic communities. This year marks over a decade of their devoted involvement in various initiatives designed to uplift these communities and enhance their rights and opportunities. Sponsorship Highlights for 2024...

Continue Reading
AMTD's Dr. Calvin Choi Solidifies Leadership in HK

Updated Category News Views 20

Dr. Calvin Choi's Reappointment: A Strategic Move Out in the world of high stakes and corporate chess, Dr. Calvin Choi is making moves that echo far beyond the boardrooms. This guy isn't just resting on his laurels; his reappointment as President of the Hong Kong Island Federation spells serious business for AMTD IDEA (NYSE: AMTD), AMTD Digital (NYSE: HKD), and by...

Continue Reading